scholarly journals Patient‐reported outcomes in adults with type 1 diabetes in global real‐world clinical practice: the SAGE study

2021 ◽  
Author(s):  
Emma G. Wilmot ◽  
Kelly L. Close ◽  
Dubravka Jurišić‐Eržen ◽  
Daniela Bruttomesso ◽  
F. Javier Ampudia‐Blasco ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Clinical Practice ◽  
Real World ◽  
Patient Reported Outcomes ◽  
Patient Reported

scholarly journals Insulin doses requirements in patients with type 1 diabetes using glargine U300 or degludec in routine clinical practice

2021 ◽  
pp. jim-2020-001633
Author(s):  
Florentino Carral San Laureano ◽  
Mariana Tomé Fernández-Ladreda ◽  
Ana Isabel Jiménez Millán ◽  
Concepción García Calzado ◽  
María del Carmen Ayala Ortega
Keyword(s):  
Type 1 Diabetes ◽  
Clinical Practice ◽  
Retrospective Study ◽  
Real World ◽  
Glycosylated Hemoglobin ◽  
Routine Clinical Practice ◽  
Insulin Analogs ◽  
Total P ◽  
Real Clinical Practice

There are not many real-world studies evaluating daily insulin doses requirements (DIDR) in patients with type 1 diabetes (T1D) using second-generation basal insulin analogs, and such comparison is necessary. The aim of this study was to compare DIDR in individuals with T1D using glargine 300 UI/mL (IGlar-300) or degludec (IDeg) in real clinical practice. An observational, retrospective study was designed in 412 patients with T1D (males: 52%; median age 37.0±13.4 years, diabetes duration: 18.7±12.3 years) using IDeg and IGla-300 ≥6 months to compare DIDR between groups. Patients using IGla-300 (n=187) were more frequently males (59% vs 45.8%; p=0.004) and had lower glycosylated hemoglobin (HbA1c) (7.6±1.2 vs 8.1%±1.5%; p<0.001) than patients using IDeg (n=225). Total (0.77±0.36 unit/kg/day), basal (0.43±0.20 unit/kg/day) and prandial (0.33±0.23 unit/kg/day) DIDR were similar in IGla-300 and IDeg groups. Patients with HbA1c ≤7% (n=113) used significantly lower basal (p=0.045) and total (p=0.024) DIDR, but not prandial insulin (p=0.241), than patients with HbA1c between 7.1% and 8% and >8%. Patients using IGla-300 and IDeg used similar basal, prandial and total DIDR regardless of metabolic control subgroup. No difference in basal, prandial and total DIDR was observed between patients with T1D using IGla-300 or IDeg during at least 6 months in routine clinical practice.

717-P: Real-World, Patient-Reported Data on Training and Use of 670G Hybrid Closed-Loop (HCL) among Children and Adults with Type 1 Diabetes (T1D)

Diabetes ◽  
2021 ◽  
Vol 70 (Supplement 1) ◽  
pp. 717-P
Author(s):  
COLLEEN BAUZA ◽  
STEPHANIE DUBOSE ◽  
ALANDRA VERDEJO ◽  
ROY BECK ◽  
RICHARD M. BERGENSTAL ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Real World ◽  
Closed Loop ◽  
Patient Reported ◽  
Reported Data

scholarly journals Quality of life in chronic conditions using patient-reported measures and biomarkers: a DEA analysis in type 1 diabetes

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Sixten Borg ◽  
Ulf-G. Gerdtham ◽  
Katarina Eeg-Olofsson ◽  
Bo Palaszewski ◽  
Soffia Gudbjörnsdottir
Keyword(s):  
Quality Of Life ◽  
Risk Factors ◽  
Type 1 Diabetes ◽  
Patient Reported Outcomes ◽  
Efficiency Analysis ◽  
Outcomes Measures ◽  
Patient Reported ◽  
The Individual

Abstract Background A chronic disease impacts a patient’s daily life, with the burden of symptoms and managing the condition, and concerns of progression and disease complications. Such aspects are captured by Patient-Reported Outcomes Measures (PROM), assessments of e.g. wellbeing. Patient-Reported Experience Measures (PREM) assess patients’ experiences of healthcare and address patient preferences. Biomarkers are useful for monitoring disease activity and treatment effect and determining risks of progression and complications, and they provide information on current and future health. Individuals may differ in which among these aspects they consider important. We aimed to develop a measure of quality of life using biomarkers, PROM and PREM, that would provide an unambiguous ranking of individuals, without presuming any specific set of importance weights. We anticipated it would be useful for studying needs and room for improvement, estimating the effects of interventions and comparing alternatives, and for developing healthcare with a broad focus on the individual. We wished to examine if efficiency analysis could be used for this purpose, in an application to individuals with type 1 diabetes. Results We used PROM and PREM data linked to registry data on risk factors, in a large sample selected from the National Diabetes Registry in Sweden. Efficiency analysis appears useful for evaluating the situation of individuals with type 1 diabetes. Quality of life was estimated as efficiency, which differed by age. The contribution of different components to quality of life was heterogeneous, and differed by gender, age and duration of diabetes. Observed quality of life shortfall was mainly due to inefficiency, and to some extent due to the level of available inputs. Conclusions The efficiency analysis approach can use patient-reported outcomes measures, patient-reported experience measures and comorbidity risk factors to estimate quality of life with a broad focus on the individual, in individuals with type 1 diabetes. The approach enables ranking and comparisons using all these aspects in parallel, and allows each individual to express their own view of which aspects are important to them. The approach can be used for policy regarding interventions on inefficiency as well as healthcare resource allocation, although currently limited to type 1 diabetes.

976-P: Evaluation of Hybrid Closed-Loop Insulin Delivery System for Patients with Type 1 Diabetes in Real-World Clinical Practice: A One-Year Qualitative Observational Study

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 976-P
Author(s):  
AHMED H. ELDIB ◽  
SHAHEEN TOMAH ◽  
SHILTON E. DHAVER ◽  
HANNAH GARDNER ◽  
MHD WAEL TASABEHJI ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Clinical Practice ◽  
Observational Study ◽  
Delivery System ◽  
Real World ◽  
Closed Loop ◽  
Insulin Delivery ◽  
Insulin Delivery System ◽  
One Year

Real-world, Patient-Reported and Clinic Data from Individuals with Type 1 Diabetes using the MiniMed 670G Hybrid Closed Loop System

2021 ◽  
Author(s):  
Stepnanie DuBose ◽  
Colleen Bauza ◽  
Alandra Verdejo ◽  
Roy W. Beck ◽  
Richard M Bergenstal ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Real World ◽  
Closed Loop ◽  
Loop System ◽  
Closed Loop System ◽  
Patient Reported
Sign in / Sign up

Export Citation Format

Share Document